Oppenheimer Holdings Weighs in on CytomX Therapeutics Inc.’s FY2016 Earnings (CTMX)
CytomX Therapeutics Inc. (NASDAQ:CTMX) – Analysts at Oppenheimer Holdings raised their FY2016 EPS estimates for CytomX Therapeutics in a research report issued on Wednesday. Oppenheimer Holdings analyst M. Gilson now expects that the brokerage will post earnings of ($1.68) per share for the year, up from their previous forecast of ($1.69). Oppenheimer Holdings also issued estimates for CytomX Therapeutics’ Q4 2016 earnings at ($0.44) EPS and FY2017 earnings at ($2.00) EPS.
Separately, Zacks Investment Research upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Tuesday, November 8th.
CytomX Therapeutics (NASDAQ:CTMX) opened at 11.21 on Friday. The firm’s 50-day moving average price is $13.25 and its 200 day moving average price is $11.76. The stock’s market cap is $408.07 million. CytomX Therapeutics has a 12-month low of $9.10 and a 12-month high of $24.68.
In other news, Director Ix L.P. Canaan sold 13,730 shares of the company’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $11.03, for a total value of $151,441.90. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 4.70% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the company. KCG Holdings Inc. bought a new stake in shares of CytomX Therapeutics during the third quarter worth approximately $211,000. Spark Investment Management LLC bought a new stake in shares of CytomX Therapeutics during the third quarter worth approximately $374,000. Northern Trust Corp increased its stake in shares of CytomX Therapeutics by 116.8% in the third quarter. Northern Trust Corp now owns 216,324 shares of the company’s stock worth $3,391,000 after buying an additional 116,552 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of CytomX Therapeutics by 0.7% in the third quarter. California State Teachers Retirement System now owns 43,130 shares of the company’s stock worth $676,000 after buying an additional 300 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of CytomX Therapeutics during the third quarter worth approximately $117,000. Hedge funds and other institutional investors own 51.95% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.
Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.